# Hemogenyx and Nitto Denko to Test Lipid Nanoparticle Delivery of FLT3 CAR mRNA > Hemogenyx signed a feasibility study with Nitto Denko to test ctLNP delivery of FLT3-CAR mRNA to human T cells. - Published: 2026-10-19T06:23:57+00:00 - Section: Partnerships - Author: News Desk - URL: https://newsforagent.com/news/2026-10-19/hemogenyx-nitto-denko-feasibility-study - Source: [Stock Titan](https://www.stocktitan.net/news/HOPHF/hemogenyx-pharmaceuticals-plc-announces-feasibility-study-gi385pyp4xi8.html) ## Key takeaways - Hemogenyx Pharmaceuticals entered a feasibility study agreement with Nitto Denko to test whether Nitto's cell-targeted lipid nanoparticles can deliver Hemogenyx's FLT3-targeting CAR mRNA to human T cells. - The in vitro study is expected to take approximately four months, and each party retains ownership of its own technology. - Hemogenyx's ongoing Phase I trial of HG-CT-1 in relapsed or refractory acute myeloid leukemia remains unaffected and is its principal focus. Hemogenyx Pharmaceuticals plc entered a feasibility study agreement with Nitto Denko Corporation to evaluate whether Nitto's cell-targeted lipid nanoparticle technology can deliver Hemogenyx's messenger RNA encoding its FLT3-targeting chimeric antigen receptor to human T cells, [Stock Titan](https://www.stocktitan.net/news/HOPHF/hemogenyx-pharmaceuticals-plc-announces-feasibility-study-gi385pyp4xi8.html) reported on October 19, 2026. The in vitro study is expected to take approximately four months. ## How the Hemogenyx and Nitto Denko Study Works Under the agreement, the parties will test whether Nitto's ctLNP drug delivery technology can carry Hemogenyx's FLT3-CAR mRNA into human T cells. Each party retains ownership of its own technology. Hemogenyx said the study is its first step toward an in vivo CAR-T approach, in which a patient's T cells are reprogrammed inside the body by an injectable medicine rather than engineered individually in a manufacturing facility. Hemogenyx's lead product candidate, HG-CT-1, is an autologous CAR-T cell therapy: each dose is made from the individual patient's own T cells, which are collected, genetically engineered and expanded outside the body before being returned to that patient. Hemogenyx said an in vivo product built on its FLT3-CAR could, if technically feasible, broaden the reach and commercial potential of its CAR-T technology. The company's ongoing Phase I clinical trial of HG-CT-1 in relapsed or refractory acute myeloid leukemia is unaffected and remains its principal focus. Dr Vladislav Sandler, Chief Executive Officer and Co-Founder of Hemogenyx Pharmaceuticals, said: "Autologous CAR-T therapy works, but every dose is a bespoke manufacturing campaign for a single patient. In vivo CAR-T offers a fundamentally different model: a drug-like product, made at scale and available off the shelf, that instructs the patient's own T cells to become CAR-T cells inside the body." Nitto Denko, based in Japan, manufactures high-performance materials, including medical-related products and services. [Nitto Denko](https://akta.pro/company-profiles/000914n/nitto-denko) agreed with Resonac Holdings in September 2026 to invest in a U.S.-based fund focused on AI hardware makers, Nikkei Asia reported. ## Hemogenyx's Funding and Manufacturing Record According to akta.pro [company records](https://akta.pro/company-data), Hemogenyx established manufacturing infrastructure in Estonia through a letter of intent with Cellin Technologies OÜ in September 2025 and a £3.0 million institutional subscription at £8.01 per share in April 2026, enabling early commercialisation of HG-CT-1 under the hospital exemption pathway. The same records show a March 2026 technology transfer of HG-CT-1 manufacturing to CDMO Made Scientific and a comparability data package submitted to the FDA. Hemogenyx was admitted to the London Stock Exchange Main Market on 23 December 2025, increasing total issued shares to 6,041,255. ## Earlier Hemogenyx Collaboration Agreements In August 2026, Hemogenyx signed a definitive collaboration agreement with Cellin Technologies OÜ for the manufacturing and clinical implementation of HG-CT-1 in Estonia under the Hospital Exemption framework, Stock Titan reported. In July 2026, Hemogenyx signed a letter of intent with the National Cancer Centre at Vilnius University Hospital Santaros Klinikos in Lithuania for a clinical and scientific collaboration focused on FLT3-positive acute myeloid leukemia and myelodysplastic syndromes, FinancialContent Business Page reported. ## What Comes Next for the Study The study is an in vitro evaluation expected to take approximately four months, with each party retaining ownership of its own technology. ## Companies in this story - [HemoGenyx company profile](https://akta.pro/company-profiles/0000ohv/hemogenyx) · website: http://www.hemogenyx.com - [Nitto Denko company profile](https://akta.pro/company-profiles/000914n/nitto-denko) · website: http://www.nitto.com --- News for Agent · https://newsforagent.com/llms.txt